Voyager Therapeutics, Inc.
VYGR evidence brief
What we can confirm
- BioSniper Score:
- 7.6 / 10
- Market Cap:
- $194.7M
- Lead Asset:
- novartis hd program (Preclinical)
What it means
What to watch
Prepared research question
What matters most for VYGR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VYGR
Voyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing genetic and other therapies for neurological diseases, with a pipeline centered on Alzheimer's disease and other CNS conditions, leveraging its TRACER capsid discovery and Voyager NeuroShuttle platforms.
Key risk: Clinical trial risks
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$194.7M
Cash Runway
—
Lead Asset
novartis hd program (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 2 clinical trials for Voyager Therapeutics, Inc..
Voyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing genetic and other therapies for neurological diseases, with a pipeline centered on Alzheimer's disease and other CNS conditions, leveraging its TRACER capsid discovery and Voyager NeuroShuttle platforms.
- Cash & equivalents of $35.8M as of 2026-06-30 [sec].
- Total revenue of $3.2M and net income of -$24.5M for the six months ended 2026-06-30 [sec].
- Accumulated deficit of $498.3M as of 2026-06-30 [sec_mda].
- Shareholders' equity of $154.4M as of 2026-06-30 [sec].
- Pipeline includes wholly-owned programs (VY7523, VY1706) and collaborations with Neurocrine and Novartis [sec_mda].
What works
- Proprietary TRACER capsid discovery platform enables high brain penetration with genetic medicines following IV dosing [sec_mda].
- Multiple collaboration agreements (with Neurocrine, Novartis, Alexion) provide non-dilutive funding and potential future royalties [sec_mda].
- Cash runway expected into 2028 based on current resources and expected collaboration reimbursements [sec_mda].
What to weigh
- Net loss of $24.5M in the first half of 2026 and accumulated deficit of $498.3M as of 2026-06-30 [sec, sec_mda].
- Significant ongoing expenses and operating losses expected for the foreseeable future due to clinical trial costs and R&D investments [sec_mda].
- Clinical programs are early-stage (Phase 1) with no approved products, so revenue is minimal ($3.2M in H1 2026) [sec].
- Forward-looking statements caution about risks in clinical development, regulatory decisions, and ability to replicate preclinical results [sec].
From the filings
Quoted directly from source documents.
Accumulated deficit
“accumulated deficit of $498.3 million”
SEC MD&A · June 30, 2026
TRACER platform description
“TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform”
SEC MD&A · August 6, 2026
VY1706 trial initiation
“Investigational New Drug clearance for VY1706 in June 2026 and plans to begin dosing in a multi-site, open-label, dose-escalation clinical trial of VY1706 in the second half of 2026”
SEC filings · July 13, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial risks — Initiation, enrollment, timing, cost, and results of planned and future clinical trials are uncertain [sec].
- Regulatory uncertainty — Expectations and decisions of regulatory authorities may differ from company plans [sec].
- Replication of results — Ability to replicate positive preclinical or prior clinical results in current/future trials is uncertain [sec].
- Financial sustainability — Continued significant expenses and operating losses expected; cash runway into 2028 but dependent on many factors [sec_mda].
What to watch
- Initial tau PET imaging efficacy data from VY7523 MAD trial expected in Q4 2026 [sec_mda].
- First dosing of VY1706 in Phase 1 trial expected in Q4 2026 [sec_mda].
- Initial acute safety data from VY1706 anticipated in early 2027 [sec_mda].
- Cash runway and expense management as company continues to incur losses [sec_mda].
Sources: News · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run Voyager Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Voyager Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.28 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
134
Total value held
$127.5M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,568,381 | $21.5M |
| armistice capital, llc | 3,500,000 | $13.5M |
| millennium management llc | 3,428,571 | $13.2M |
| vestal point capital, lp | 3,002,936 | $11.6M |
| vanguard capital management llc | 2,283,253 | $8.8M |
| opaleye management inc. | 1,150,000 | $4.4M |
| erste asset management gmbh | 1,095,141 | $4.2M |
| geode capital management, llc | 1,049,978 | $4.1M |
| state street corp | 948,226 | $3.7M |
| dimensional fund advisors lp | 875,568 | $3.4M |
Showing top 10 of 134 institutional holders of Voyager Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 7.1%
- Days to cover
- 6.8
- Shares short
- 3,663,210
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VYGR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Voyager Therapeutics, Inc.?
Voyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing genetic and other therapies for neurological diseases, with a pipeline centered on Alzheimer's disease and other CNS conditions, leveraging its TRACER capsid discovery and Voyager NeuroShuttle platforms.
What is Voyager Therapeutics, Inc.'s lead drug candidate?
Voyager Therapeutics, Inc.'s most advanced tracked candidate is novartis hd program (Preclinical) for Huntington's disease.
Who is the CEO of Voyager Therapeutics, Inc.?
Dr. Alfred W. Sandrock Jr., M.D., Ph.D. is the chief executive officer of Voyager Therapeutics, Inc. (VYGR).
Where is Voyager Therapeutics, Inc. headquartered?
Voyager Therapeutics, Inc. (VYGR) is headquartered in Lexington, MA, United States.
What therapeutic areas does Voyager Therapeutics, Inc. focus on?
Voyager Therapeutics, Inc. develops therapies across Rare Disease, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.